Tag: marijuana

Top police chiefs say smell of cannabis is a ‘sign of crime’ that can make even them feel ‘unsafe’… and frontline officers should ‘do something about it’

Britain’s top police chiefs today urge their officers to crack down on cannabis.

The country’s longest-serving chief constable admits the smell of the drug is a ‘sign of crime and disorder’ which makes even him ‘feel unsafe’.

Sir Andy Marsh, who leads the College of Policing, said frontline officers should ‘do something about it’.

He is backed by Greater Manchester Police Chief Sir Stephen Watson and Merseyside Chief Constable Serena Kennedy.

In a joint intervention following recent calls for decriminalisation, they tell future police leaders they must listen to their communities and be prepared to take a tougher line.

Launching a new leadership programme for policing, they acknowledged forces were in a ‘foot race for public confidence’ and officers can no longer ignore what has traditionally been perceived as the ‘little stuff’. 

Sir Andy, who is the officer in charge of police standards, said: ‘In my community, my kids are too frightened to use the bus stop because it always stinks of cannabis.’

He told the Mail ‘policing is about creating an environment that people feel safe in’ and said: ‘I’m speaking from personal experience and people I talk to, if I walk through a town, city, or even village centre and I smell cannabis, it does actually have an impact on how safe I feel.

‘One definition of what police should be doing is – [if] something [is] happening which does not feel right, someone ought to do something about it.’

He added: ‘For me, the smell of cannabis around communities, it feels like a sign of crime and disorder.’

The call for action comes after figures on Sunday revealed that three in four people caught with the drug last year were let off with an informal warning or community resolution.

In the year to September 2024, 68,513 people were found in possession of cannabis, but only 17,000 were charged, according to data released under Freedom of Information laws.

Mayor of London Sir Sadiq Khan has called for the decriminalisation of possession when it involves small amounts of the drug. 

But recently judges have warned that cannabis is ‘not a benign drug’ after a series of horrific cases, including a samurai sword rampage in Hainault, east London, where a schoolboy was killed and four others seriously injured by a drug-crazed Brazilian who had a £100-a-day habit.

The head of Merseyside Police said of cannabis: ‘The public should absolutely expect us to take positive action around those things and hold us to account over it. 

‘We have to work with our communities, it’s no longer good enough to inflict priorities on them, we have to hear their voices and make them part of the problem-solving.’

Keep reading

Marijuana Users In Iowa Are Engaged And Active Citizens, Survey Shows—Smashing ‘Lazy Stoner’ Stereotypes

For many years, cannabis users were characterized as a cult of stoners: young, often unemployed, party animals. That sector still exists in some form, however, many of today’s cannabis consumers are “middle American” adults, employed, own a home, vote regularly, pay their taxes and are involved in their communities.

That is the general profile of adult cannabis consumers across the country and in Des Moines, according to a recent survey by Consumer Research Around Cannabis/The Media Audit.

The Media Audit, the parent company of Consumer Research Around Cannabis, is an international research company serving 80+ local markets in the U.S. and Canada for more than 20 years. It started gathering data about cannabis use and attitudes in 2016.

Although the sale of adult recreational cannabis is illegal in Iowa, the survey found 16.2 percent of all adults age 18+ in Des Moines said they used or bought cannabis during the past month, or the statistical equivalent of approximately 140,000 adults.

The smallest percentage in the following table, monthly usage in Des Moines, is still substantial—and suggests a pent-up market. Unleashing the recreational cannabis market in Des Moines and all of Iowa would likely generate jobs and significant taxes for the state—money now escaping across the borders.

Keep reading

Marijuana Use Is Tied To ‘Significantly Higher Sexual Desire And Arousal,’ New Study Shows

Marijuana use is associated with increased sexual desire and arousal, as well as lower levels of sexual distress, new research shows.

The report, a doctoral thesis out of Queens University in Canada, includes two separate studies: an online survey of 1,547 cannabis users as well as a 28-day diary analysis of 115 individuals—87 of whom were marijuana users, while 28 were infrequent users or nonusers.

“More frequent cannabis use was linked with greater daily sexual desire,” wrote author Kayla M. Mooney. “On sexual activity days, participants reported significantly higher sexual desire and arousal on days they used cannabis compared to non-use days.”

“Across all study days (regardless of sexual activity), participants reported significantly higher sexual desire and lower sexual distress on days they used cannabis compared to non-use days,” the study continues, noting the findings could help inform both both sex therapy and general psychotherapy.

As for the online survey, “Approximately half of the sample reported sexual motivations for cannabis use, most commonly to enhance aspects of the sexual response,” according to the abstract.

The new report—which itself calls the relationship between cannabis and sexual functioning “complicated”—adds to a growing body of research about the subject.

For example, late last year a study found that cannabis-infused vaginal suppositories seemed to reduce sexual pain in women after treatment for gynecological cancer. Combining the suppositories with online exercises in “mindful compassion” offered patients even more substantial benefits.

“The outcomes favoured the [combined] group,” that research said “in which sexual function, levels of sexual arousal, lubrication, and orgasm increased, and the levels of sexual pain decreased.”

Earlier research also found that administration of a broad-spectrum, high-CBD vaginal suppository was associated with “significantly reduced frequency and severity of menstrual-related symptoms” as well as the symptoms’ negative impacts on daily life.

As for sexual fulfillment, a separate study last year found that while alcohol might be effective to “facilitate” sex, marijuana is better at enhancing sexual sensitivity and satisfaction.

While alcohol increased some elements of sexual attraction—including making people feel more attractive, more extroverted and more desirous—people who used marijuana “have more sensitivity and they are more sexually satisfied than when they consume alcohol,” authors wrote.

Keep reading

8 In 10 Marijuana Consumers Use It As A Substitute For Prescription Drugs, New Survey Finds

A whopping eight in 10 marijuana consumers say they use cannabis, at least in part, as an alternative to traditional prescription drugs, according to a new poll.

The survey from the cannabis telehealth platform NuggMD, which was shared exclusively with Marijuana Moment, asked cannabis consumers a simple question: “Do you use cannabis as a replacement for prescription medication?”

Of the 485 respondents, 79.6 percent affirmed that they did, in fact, use marijuana as a substitute to pharmaceuticals, compared to 20.4 percent who said they did not.

“Pharmaceutical interests know the substitution effect cannabis has on their products is real,” Andrew Graham, head of communications at NuggMD, told Marijuana Moment. “Federal prohibition locks in a lot of demand for their addictive and potentially fatal drugs by depriving millions of Americans of legal access to the plant, and I can’t name a single interest aligned with Big Pharma that’s stated support for ending it.”

“Our newest poll shows the substitution effect may well be a lot higher than the pharma industry thinks that it is,” he said. “It estimates that around 40 million Americans use cannabis to some degree as a replacement for prescription drugs. That’s costing Big Pharma billions annually in lost profits.”

“I genuinely want Big Pharma to see this data and decide to spend yet more resources fighting against the plant. Because the more noise they make against cannabis, the more popular our movement becomes. They are that unpopular,” Graham added.

Notably, a majority of respondents in the survey sample did not report having a state medical cannabis card, indicating that the substitution effect extends beyond the registered patient population.

Keep reading

Letting Marijuana Users Have Guns Poses ‘A Clear Danger,’ Trump’s Solicitor General Tells Supreme Court

In a recent filing with the U.S. Supreme Court, the Trump-led Department of Justice (DOJ) is doubling down on arguments made under former President Joe Biden that users of illegal drugs—including marijuana—”pose a clear danger of misusing firearms.”

That risk, DOJ contends, justifies the longstanding federal prohibition on gun ownership by drug consumers—known as Section 922(g)(3)—despite the Constitution’s broad Second Amendment protections.

In a petition for review by the high court, U.S. Solicitor General D. John Sauer argues that despite recent appeals court decisions calling the constitutionality of the firearms ban into question, the restriction is nevertheless lawful.

“Section 922(g)(3) complies with the Second Amendment,” the government’s June 2 filing in the case, U.S. v. Hemani, says. “That provision targets a category of persons who pose a clear danger of misusing firearms: habitual users of unlawful drugs.”

Some lower courts have said the government’s blanket ban on gun and ammunition possession infringes on the Second Amendment—at least as applied to certain individual cases—because there’s no historical justification for such a broad restriction on an entire category of people.

But in the appeal petition in Hemani, Trump’s solicitor general said the ban is necessary and narrowly tailored enough to survive the legal challenge.

The federal statute “bars their possession of firearms only temporarily and leaves it within their power to lift the restriction at any time; anyone who stops habitually using illegal drugs can resume possessing firearms.”

Notably, while the government mentions “habitual” users of illegal drugs 40 times in its filing, that word does not itself appear in 922(g)(3). The language of the statute prohibits anyone “who is an unlawful user of or addicted to any controlled substance” from purchasing or possessing firearms or ammunition.

A reply brief from Hemani’s lawyers is due to the Supreme Court by July 21.

While DOJ is asking the high court to take up the Hemani case, at least two other, similar cases are waiting in the wings: U.S. v. Cooper and U.S. v. Baxter both of which also hinge on the constitutionality of 922(g)(3).

In Cooper, an Eighth Circuit U.S. Court of Appeals panel dismissed a three-year prison sentence against a person convicted for possession of a firearm while being an active user of marijuana. Judges in that case ruled that government’s prohibition on gun ownership by drug users is justified only in certain circumstances—not always.

“Nothing in our tradition allows disarmament simply because [the defendant] belongs to a category of people, drug users, that Congress has categorically deemed dangerous,” their ruling said.

In Baxter, the Eighth Circuit ruled 922(g)(3) unconstitutional as applied to the facts in the case.

Judges in that case wrote that there were insufficient factual findings in the record “for this Court to review Baxter’s as-applied Second Amendment challenge.” Nevertheless, the they wrote, “We reverse the district court’s ruling on Baxter’s as-applied Second Amendment challenge and remand to the district court for further proceedings consistent with this opinion.”

Keep reading

Nebraska AG Sends Threat Letters To Retailers Over Alleged Sales Of Illegal THC Products

The owners of 82 smoke and vape shops and other THC-friendly retailers in Lincoln are receiving cease and desist letters this week from Nebraska Attorney General Mike Hilgers (R) about selling THC-containing products.

Hilgers, the state’s top prosecutor, ramped back up his push to get stores to stop selling delta-8, delta-9 and other products containing tetrahydrocannabinol that he argues offer people an unregulated, unsafe, illegal way to get high.

Store owners in several cities that Hilgers has targeted have argued state law is unclear about the legality of selling the products. Some have argued that federal law might have a loophole allowing it.

Hilgers had said he would pause his efforts to warn and then sue retailers still offering the targeted THC products if the Legislature in the 2025 session passed a bill to clearly make them illegal in the state, which stalled. The bill is likely to return in 2026.

His office, which also files civil cases to enforce state law, has sent the letters to 204 stores statewide alleging unfair business practices, deception and violations of safety requirements for food. That tally includes 104 stores in Omaha, four in Kearney and three in Nebraska City.

Keep reading

DEA Judge Shuts Down Cannabis Manufacturing Case Without Hearing, Company Plans Legal Challenge

The company behind the application, MMJ BioPharma Cultivation, is now preparing to challenge the ruling in federal court and call for the judge’s recusal.

The ruling was issued by DEA Chief Administrative Law Judge John Mulrooney II, who dismissed the company’s bid for a marijuana bulk manufacturing license after more than six years of delays. MMJ BioPharma said the decision came without warning and without any opportunity to present evidence or respond to agency claims—calling it a “procedural ambush.”

“This isn’t regulation—it’s an illegal ambush,” said MMJ CEO Duane Boise, who said the company had complied with all requirements under the Controlled Substances Act and FDA pathways.

MMJ, which is developing cannabis-based medicines for Huntington’s disease and multiple sclerosis, submitted a legally binding supply agreement in March 2024 with a DEA-licensed Schedule I facility. The agreement included specific sourcing protocols, defined volume, and DEA Form 222 compliance. Despite that, Mulrooney’s June 16 ruling ignored the document entirely and blocked it from being entered into the record.

Boise accused the DEA of demanding the agreement and then refusing to acknowledge it once submitted. “The agency cannot demand a document, receive it, then declare it irrelevant behind closed doors,” he said.

The order also reversed a previous determination by another administrative judge that certain disputed facts warranted a hearing. Instead, Mulrooney cited internal communications from a DEA investigator that MMJ was never allowed to challenge or respond to—raising concerns of ex parte communications and due process violations.

Keep reading

Why Is Texas Supporting Psychedelics Research While Criminalizing Cannabis?

Texas just announced it will invest $50 million into studying ibogaine, a powerful psychedelic drug that remains illegal at the federal level. The goal? To develop it into a potential Food and Drug Administration-approved treatment for conditions like opioid use disorder, PTSD and depression; especially among veterans.

On the surface, this might sound like a bold and progressive move. But here’s the irony: at the very same time, Texas continues to criminalize cannabis and might soon even outlaw hemp-derived THC products.

Let’s break this down. Cannabis, a plant with centuries of use, decades of medical data and broad public support remains illegal for adult use in Texas. Despite overwhelming national support for legalization—a staggering 88 percent of Americans now back medical or recreational cannabis use)—the state has chosen to double down on prohibition, with lawmakers sending Gov. Greg Abbott (R) a bill that would outlaw consumable hemp products with any traces of THC. He has until Sunday to decide whether to allow that ban to take effect.

Even worse, prohibition isn’t stopping anything. The black market is thriving in Texas. Cartels and illicit operators flood the state with unregulated, untested cannabis. No taxes are collected, no consumer protections exist and legal hemp retailers are now being threatened. It is a misguided public safety argument deluded by a lack of facts and science, political conservatism, contradictory business objectives and outdated stigmas.

Meanwhile, ibogaine, a hallucinogenic alkaloid that can induce intense psychedelic experiences, is now the subject of a $50 million state-funded research push. The same lawmakers who claim cannabis is too dangerous and not well studied are throwing their support behind a compound with far less research and much more uncertainty with the intent of studying it.

This isn’t a critique of psychedelic medicine. Ibogaine may very well hold incredible therapeutic value. But if Texas is willing to support cutting-edge, controversial treatments for serious mental health and addiction issues, why not start with widely available data and access to cannabis? Cannabis has already been shown to help with chronic pain, anxiety, sleep, seizures and opioid dependency.

Keep reading

Cannabis extract proves to be highly effective at killing the most dangerous animals in the world

Every year, mosquito-borne diseases cut short more than a million lives across the globe, outpacing every other animal threat to humanity. The rising toll has public-health teams scrambling for fresh combat tools, especially as traditional chemical sprays lose their edge.

That loss stems from two hard truths. First, the very pyrethroid insecticides that once worked wonders now linger in soil and water, nudging delicate ecosystems off balance.

Second, mosquitoes adapt fast. Larvae soaking in tainted puddles and adults drifting through treated neighborhoods increasingly shrug off doses that once killed them.

Controlling the pests at their waterborne stage is vital, yet options that stay potent without harming everything else remain limited.

Cannabis, CBD, and mosquitoes

Recent research published in the journal Insects points to a solution hiding in plain sight: the hemp plant, Cannabis sativa.

After air-drying and grinding ordinary hemp leaves, scientists at The Ohio State University led by Erick Martinez Rodriguez extracted cannabidiol (CBD) and added the concentrate to cups of water teeming with yellow fever mosquito larvae.

Within 48 hours, both a strain that laughs at common insecticides and a non-resistant strain were wiped out.

“Mosquitoes are one of the deadliest animals in the world, mainly because as adults they serve as vectors of disease,” Rodriguez explained.

From resistance to vulnerability

Two important findings jumped out. The first was total mortality: every mosquito larva exposed to sufficient CBD died by the two-day mark, regardless of its genetic armor.

The second was efficiency. While industrial chemicals often push resistance higher with every generation, CBD’s effect cut straight through those defenses. Doses varied, but even modest concentrations proved lethal to all mosquito larvae.

“If you compare the amount of hemp extract needed to kill 50 % of the population to other synthetic conventional insecticides, it is on the high side, but when you compare it side by side to other natural extracts we have tested in our lab, only a relatively low amount is required to produce high mortality values in larvae,” said Martinez Rodriguez.

Keep reading

Exploring Cannabis sativa L for Anti-Alzheimer Potential: An Extensive Computational Study including Molecular Docking, Molecular Dynamics, and ADMET Assessments

Abstract

Introduction: Cholinesterase enzymes play a pivotal role in hydrolyzing acetylcholine, a neurotransmitter crucial for memory and cognition, into its components, acetic acid, and choline. A primary approach in addressing Alzheimer’s disease symptoms is by inhibiting the action of these enzymes.

Methods: With this context, our study embarked on a mission to pinpoint potential Cholinesterase (ChE) inhibitors using a comprehensive computational methodology. A total of 49 phytoconstituents derived from Cannabis sativa L underwent in silico screening via molecular docking, pharmacokinetic and pharmacotoxicological analysis, to evaluate their ability to inhibit cholinesterase enzymes. Out of these, two specific compounds, namely tetrahydrocannabivarin and Δ-9- tetrahydrocannabinol, belonging to cannabinoids, stood out as prospective therapeutic agents against Alzheimer’s due to their potential as cholinesterase inhibitors. These candidates showcased commendable binding affinities with the cholinesterase enzymes, highlighting their interaction with essential enzymatic residues.

Results: They were predicted to exhibit greater binding affinities than Rivastigmine and Galantamine. Their ADMET assessments further classified them as viable oral pharmaceutical drugs. They are not expected to induce any mutagenic or hepatotoxic effects and cannot produce skin sensitization. In addition, these phytoconstituents are predicted to be BBB permeable and can reach the central nervous system (CNS) and exert their therapeutic effects. To delve deeper, we explored molecular dynamics (MD) simulations to examine the stability of the complex formed between the best candidate (Δ-9-tetrahydrocannabinol) and the target proteins under simulated biological conditions. The MD study affirmed that the ligand-ChE recognition is a spontaneous reaction leading to stable complexes.

Keep reading